Related Experiment Video
Updated: Jun 29, 2026
06:57
In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
Published on: February 20, 2020
Cutaneous leishmaniasis: progress towards a vaccine.
Pascal Launois1, Fabienne Tacchini-Cottier, Marie-Paul Kieny
1WHO-Immunology Research and Training Center, Department of Biochemistry, University of Lausanne, Chemin des Boveresses, 155, CH-1066 Epalinges, Switzerland. pascal.launois@unil.ch
Expert Review of Vaccines
|October 11, 2008
Summary
Developing vaccines against Leishmania parasites is a priority due to the lack of prevention and treatment options for leishmaniasis. Research shows promising results with live-attenuated parasites, protein, DNA, and dendritic cell vaccines.
Area of Science:
- Parasitology
- Immunology
- Vaccinology
Background:
- Leishmaniases are vector-borne protozoan parasitic diseases with no current prevention methods.
- Existing therapies for leishmaniasis are expensive, poorly tolerated, and not always effective.
- Natural immunity following recovery from infection provides a basis for vaccine development.
Purpose of the Study:
- To review recent advancements in vaccine development for leishmaniasis, particularly the cutaneous form.
- To explore novel vaccination strategies against Leishmania infection.
Main Methods:
- Review of scientific literature on leishmaniasis vaccine research.
- Analysis of evidence from animal studies on various vaccine candidates.
- Examination of emerging strategies including vector saliva immunization and dendritic cell vaccination.
Main Results:
- Live-attenuated Leishmania, purified proteins, and DNA vaccines have shown protective effects in animal models.
- Immunization against insect vector saliva may enhance conventional vaccine efficacy.
- Dendritic cell-based vaccination is a potential new tool for leishmaniasis prevention.
Conclusions:
- Vaccination represents a crucial strategy to combat leishmaniasis.
- Multiple vaccine approaches, including novel strategies, show promise for controlling Leishmania infections.
- Further research into these diverse vaccine platforms is warranted.
Related Concept Videos
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:24Smallpox
Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.